Over the past year, we’ve seen a sea change in drug discovery. The biopharmaceutical industry is no longer merely reacting to post-pandemic corrections; it is actively restructuring for a new era of “strategic selectivity.” Our latest whitepaper, State of Play 2025, explores the macro-economic and scientific shifts defining this pivotal year.
For C-suite leadership, the narrative is clear: value-driven investment has returned. While the “free-flowing” capital of 2021 is gone, Q3 2025 saw a 70% surge in venture funding directed toward high-validation assets. This “Funding Renaissance” is occurring alongside a massive technological inflection point—where AI-driven discovery is no longer a theoretical promise but a clinical reality.
However, challenges remain. The industry is currently grappling with a $350 billion patent cliff and the long-term R&D implications of the Inflation Reduction Act (IRA). From the decoupling of Chinese supply chains to the “Talent Paradox” in our workforce, the decisions made today by CEOs and CSOs will determine the survivors of this decade.
Download the full whitepaper to explore:
- In-depth analysis of the 2025 FDA novel drug approvals.
- The impact of the “AI Inflection Point” on development timelines.
- Regional breakdowns of the San Diego, SF Bay Area, and Boston hubs.
- M&A trends and the $350B revenue risk through 2029.
[Button: Download Whitepaper]
Contact us today to discuss how these trends impact your 2025-2026 strategic roadmap.